Q-omics provides the consensus-scored SH3D19 profile across patient tissues and cancer cell-line models. SH3D19 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SH3D19 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, SH3D19 protein abundance shows 31,789 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where SH3D19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3D19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3D19 survival associations across molecular data types. SH3D19 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3D19 RNA expression–survival associations across cancer types. High SH3D19 expression shows favorable associations in KIRC, UVM, READ, BRCA, UCS and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SH3D19 RNA expression.
This table summarizes SH3D19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SH3D19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3D19 shows lower tumor expression in BLCA, LUSC, KICH, LUAD, UCEC and BRCA. The BLCA box plot shows higher SH3D19 RNA expression in normal versus tumor tissue (log2 FC = −1.658, t-test p = .001).
This table shows molecular features associated with SH3D19 in patient tissues and cancer cell lines. In patient samples, SH3D19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3D19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
